
Abbott Labs (ABT) Stock Forecast & Price Target
Abbott Labs (ABT) Analyst Ratings
Bulls say
Abbott Laboratories is projected to achieve organic sales growth of 6.0-7.0% by 2025, with current consensus estimates indicating a 6.4% year-over-year increase. Notable business segments, such as Electrophysiology and Structural Heart, have demonstrated strong organic growth of 13.7% and 11.3% year-over-year, respectively, bolstered by product launches and regulatory approvals in key markets. Abbott's robust balance sheet and a consistent history of increasing dividends for over 50 years further enhance its outlook, positioning the company favorably for future growth opportunities.
Bears say
Abbott Laboratories faces significant challenges that contribute to a negative outlook, primarily due to a substantial decline in Covid-19 testing revenue, which fell from $265 million in Q3'24 to $69 million in Q3'25, highlighting the ongoing impact of reduced testing demands. Additionally, the company is contending with greater macroeconomic pressures, including inflation and foreign exchange impacts, which further strain financial performance. The lagging sales in key markets, especially in diagnostics and the impact of funding cuts for HIV testing, compound these issues, leading to a mixed financial performance and a cautious view on future growth prospects.
This aggregate rating is based on analysts' research of Abbott Labs and is not a guaranteed prediction by Public.com or investment advice.
Abbott Labs (ABT) Analyst Forecast & Price Prediction
Start investing in Abbott Labs (ABT)
Order type
Buy in
Order amount
Est. shares
0 shares